In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Nycomed, Takeda Satifies Both Strategic And Financial Objectives

Executive Summary

Takeda Pharmaceutical Co.'s $13.7 billion purchase of privately held Nycomed International Management is undoubtedly pricey, at over three times the Swiss group's 2010 revenues. But because it satisfies a number of strategic and financial imperatives, the deal - Takeda's largest ever - may be worth the cost.

Related Content

Private Equity Reinvents Its Take On Biopharma
Priming Russia’s Pharma Industry For Innovation
Takeda’s Strategic Run Up To Nycomed
Key Considerations For Launching Pharmaceutical Products In Emerging Markets
Nycomed US Plans Growth Through Acquisition
Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Takeda's Global Ambition


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts